✦ LIBER ✦

Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study

✍ Scribed by Hotta, N.; Toyota, T.; Matsuoka, K.; Shigeta, Y.; Kikkawa, R.; Kaneko, T.; Takahashi, A.; Sugimura, K.; Koike, Y.; Ishii, J.; Sakamoto, N.

Book ID: 121796667
Publisher: American Diabetes Association
Year: 2001
Tongue: English
Weight: 140 KB
Volume: 24
Category: Article
ISSN: 0149-5992
DOI: 10.2337/diacare.24.10.1776

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of an aldose reductase inhibitor

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study

✍ Y Goto; N Hotta; Y Shigeta; N Sakamoto; R Kikkawa 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 811 KB

Efficacy and safety of monotherapy with

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

✍ Kaku, Kohei; Watada, Hirotaka; Iwamoto, Yasuhiko; Utsunomiya, Kazunori; Terauchi 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 316 KB